Sentiment Summary
Recent Events
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
First quarter 2026 earnings release and conference call scheduled for April 30, 2026. Analysts forecast a loss per share, reflecting charges from recent acquisitions, forecasted. High importance estimated as earnings typically drive significant price movement, scheduled.
Bristol-Myers Squibb is scheduled to release its Q1 2026 financial results on April 30, 2026. Analysts forecast an EPS of around $1.46 and revenue of $10.85 billion, a slight year-over-year decline forecasted. Medium importance is estimated as earnings releases typically cause 5-10% volatility.
Reported Q1 2026 adjusted EPS of $2.65 and revenue of $15.0 billion, both beating analyst expectations. Raised full-year 2026 adjusted EPS guidance to $14.08 - $14.28.
The U.S. FDA accepted for Priority Review the New Drug Application (NDA) for the investigational once-daily single-tablet HIV treatment regimen, bictegravir/lenacapavir (BIC/LEN) on 2026-04-29. This major regulatory milestone is estimated to have a high price impact of over 10% due to the significance of the HIV franchise.
Pfizer announced on April 29, 2026, that its blood-cancer drug Elrexfio met its primary endpoint in a Phase 3 study, significantly improving progression-free survival in patients with relapsed or refractory multiple myeloma.
The company's antibody-drug conjugate (ADC) SYS6051 received approval from the US FDA on 2026-04-29 to commence clinical trials for advanced solid tumors, following a similar approval from China's NMPA in April 2026; Medium importance estimated due to the significant regulatory milestone, with positive impact expected.
The New Drug Application (NDA) for sovleplenib for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA) was accepted and granted Priority Review and Breakthrough Therapy Designation by the China National Medical Products Administration (NMPA).
Announced on 2026-04-29 that its self-developed Class 1 new drug, HS-10522 tablets, received two clinical trial approvals from China's NMPA for treating uncontrolled hypertension and primary aldosteronism. Medium importance is assigned as clinical approvals for new drugs typically impact price by >=5%.
Announced on 2026-04-29 that its B7-H3 targeted ADC, HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating advanced castration-resistant prostate cancer. Medium importance is assigned as Breakthrough Therapy Designation is a significant milestone likely impacting price by >=5%.
Shareholders approved the issuance of RMB-denominated shares for a future listing on the Shanghai Stock Exchange's Sci-Tech board (STAR Market) during an extraordinary general meeting on April 29, 2026. This is estimated to have a medium price impact (>=5%) due to potential capital expansion; approval is scheduled.
Announced the first patient enrollment in the Phase III registrational clinical trial of Orelabrutinib for Systemic Lupus Erythematosus (SLE) on 2026-04-29. Medium importance estimated as this key clinical milestone is likely to cause ≥5% price impact.
Announced an ongoing share buyback program on 2026-04-29, with multiple repurchases conducted throughout April 2026; low impact estimated for routine buyback, expected.
Announced that Mr. Tian Zhoushan and Mr. Li Dakui retired as directors of the company on 2026-04-29; low impact estimated for administrative change, expected.
Ivonescimab (PD-1/VEGF bispecific antibody) received multiple upgraded Class I recommendations in the 2026 Chinese Society of Clinical Oncology (CSCO) guidelines for Non-Small Cell Lung Cancer (NSCLC), strengthening its position as a preferred first-line treatment. Estimated price impact ≥10% due to major clinical guideline upgrade. Expected.
Reported Q1 2026 results on 2026-04-28, achieving a net profit of CNY 328.01 million, a significant turnaround from a net loss of CNY 254.14 million in the same period last year. Revenue grew 24.76% YoY to CNY 656.21 million. Estimated price impact >=10% due to significant financial turnaround and the release is scheduled.
On April 28, 2026, the U.S. FDA's CDER proposed to withdraw the approval for Amgen's drug Tavneos due to effectiveness and safety concerns. High importance is estimated as drug withdrawals significantly impact revenue and reputation.
Announced on April 28, 2026, Pfizer reached settlement agreements with generic drug manufacturers, extending the U.S. patent exclusivity for its blockbuster heart disease drug Vyndamax to June 1, 2031.
Announced a strategic agreement granting AbbVie an exclusive option to acquire Kestrel Therapeutics for up to $1.45 billion, centered on its pan-KRAS inhibitor KST-6051 for solid tumors.
Submitted an application to the U.S. FDA for upadacitinib (Rinvoq) for the treatment of adult and adolescent patients with severe alopecia areata.
Received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an AI-powered coronary imaging platform.
Subsidiary clinical trial approval for SHR-2173 (myasthenia gravis) on April 28, 2026; low importance reflects expected >1% price impact. scheduled
The Board of Directors resolved on 2026-04-28 to terminate the post-IPO restricted share unit (RSU) plan and proposed the adoption of a new 2026 Share Plan, subject to shareholder approval. Low importance is assigned as administrative share plan changes typically have >=1% price impact.
On April 28, 2026, the FDA announced Amgen's participation in a new proof-of-concept pilot for real-time clinical trials (RTCT) for Imdelltra. Low importance is estimated as this is a procedural pilot program.
Announced Q1 2026 results on April 27, 2026, reporting a 28.8% YoY increase in revenue to RMB 12.44 billion and a 71.7% YoY increase in adjusted non-IFRS net profit to RMB 4.60 billion, beating expectations; high impact estimated due to significant profit growth, expected.
Announced on 2026-04-27 that its A-share listed subsidiary, CSPC Innovation Pharmaceutical, reported a net loss of RMB 93.85 million for Q1 2026; Medium importance estimated due to the substantial loss in a major subsidiary, with negative impact expected.
Announced on 2026-04-27 that study results for Mesutoclax and Orelabrutinib were accepted for the 2026 ASCO Annual Meeting, with Mesutoclax selected for oral presentation. Medium importance estimated as an oral presentation at a major conference is likely to cause ≥5% price impact.
Submitted an application to the U.S. FDA for SKYRIZI (risankizumab) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn's disease.
Granted 15.39 million restricted share units (0.87% of total shares) on 2026-04-24 under the 2023 Equity Incentive Plan. Low importance estimated as the minor dilution is likely to cause ≥1% price impact.
Received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA) for trenibotulinumtoxinE, requesting additional information on manufacturing processes.
On 2026-04-24, shareholders approved the 2026 Incentive Stock Program and Kevin Conroy was appointed to the Board of Directors, increasing the board size from twelve to thirteen members.